2020
DOI: 10.1093/ecco-jcc/jjaa018
|View full text |Cite
|
Sign up to set email alerts
|

Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience

Abstract: Background Acute severe ulcerative colitis is a high stakes event with significant numbers still requiring emergent colectomy, representing a need to establish alternative medical management options. We report a case series of tofacitinib as rescue therapy in biologic-experienced patients with acute severe ulcerative colitis. Methods Four patients were identified over a 1-year period at our institution who initiated tofacitin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
41
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 63 publications
(42 citation statements)
references
References 8 publications
1
41
0
Order By: Relevance
“…45 There is also very limited evidence for its use in the setting of ASUC. 46 For these reasons, the panel considered its use inappropriate in nearly all settings although it was noted that its rapid offset of action could be of theoretical benefit.…”
Section: Continuing Medical Therapymentioning
confidence: 99%
“…45 There is also very limited evidence for its use in the setting of ASUC. 46 For these reasons, the panel considered its use inappropriate in nearly all settings although it was noted that its rapid offset of action could be of theoretical benefit.…”
Section: Continuing Medical Therapymentioning
confidence: 99%
“…Further clinical trials with different biologics or small molecules are also needed in this setting. 32,33 In conclusion, we have reported the favorable short-term and long-term outcomes of IFX treatment in Korean patients with ASUC, pointing to IFX as an effective therapeutic option in such a critical situation. We believe that IFX can be considered as a first-line option for the treatment of ASUC, in highly selected patients, who cannot receive initial therapy with IVCS.…”
Section: Discussionmentioning
confidence: 77%
“…67 In another case series of again only 4 patients all patients achieved remission, and no one had to undergo colectomy. 68 In a recent case series of 5 ASUC patients who had failed anti-TNF therapy, 3 improved under tofacitinib therapy while 2 eventually had to undergo acolectomy. 69 Further prospective studies are needed.…”
Section: Optimal Dose Targeting Is Primordialmentioning
confidence: 99%